Broadfin Capital’s Derma Sciences DSCI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q1
– Sell
-2,562,104
Closed -$13.3M – 72
2016
Q4
$13.3M Hold
2,562,104
– – 1.48% 19
2016
Q3
$12M Hold
2,562,104
– – 1.07% 27
2016
Q2
$10.1M Hold
2,562,104
– – 0.98% 28
2016
Q1
$7.94M Hold
2,562,104
– – 0.77% 35
2015
Q4
$11.7M Buy
2,562,104
+200,000
+8% +$948K 0.72% 37
2015
Q3
$11.1M Buy
2,362,104
+44,615
+2% +$288K 0.62% 40
2015
Q2
$16.6M Buy
2,317,489
+187,012
+9% +$1.41M 0.89% 33
2015
Q1
$18M Buy
2,130,477
+273,600
+15% +$2.33M 1.41% 16
2014
Q4
$17.3M Buy
1,856,877
+32,500
+2% +$283K 1.5% 19
2014
Q3
$15.2M Hold
1,824,377
– – 1.59% 17
2014
Q2
$21.1M Buy
1,824,377
+154,600
+9% +$1.59M 2.06% 15
2014
Q1
$21.2M Buy
1,669,777
+798,179
+92% +$10.3M 2.05% 13
2013
Q4
$9.43M Buy
871,598
+100,000
+13% +$1.16M 1.24% 27
2013
Q3
$9.6M Sell
771,598
-3,402
-0.4% -$47K 1.7% 19
2013
Q2
$10.3M Buy
+775,000
New +$10M 2.02% 16

Other funds holding DSCI

Broadfin Capital's DSCI Position: Q1 2017 in Review

Broadfin Capital sold out of Derma Sciences (DSCI) in Q1 2017, closing a stake of 2,562,104 shares — an estimated $13.3M sold.

Broadfin Capital first reported a position in DSCI in Q2 2013 and held it in 15 quarters. The position peaked at $21.2M in Q1 2014. 1 fund tracked by Wall St. Rank holds DSCI as of Q1 2017.

  • Broadfin Capital reported no remaining Derma Sciences position as of Q1 2017 after selling out during the quarter.
  • Broadfin Capital sold 2,562,104 Derma Sciences shares in Q1 2017, an estimated $13.3M.
  • Broadfin Capital first reported a position in Derma Sciences in Q2 2013 and held it in 15 quarters.
  • Broadfin Capital's Derma Sciences position peaked at $21.2M in Q1 2014.
  • 1 fund tracked by Wall St. Rank held Derma Sciences as of Q1 2017.

Based on Broadfin Capital's 13F filing for Q1 2017, filed 15 May 2017.